A transcriptome-wide association study identifies novel candidate susceptibility genes for prostate cancer risk. 2022

Duo Liu, and Jingjing Zhu, and Dan Zhou, and Emily G Nikas, and Nikos T Mitanis, and Yanfa Sun, and Chong Wu, and Nicholas Mancuso, and Nancy J Cox, and Liang Wang, and Stephen J Freedland, and Christopher A Haiman, and Eric R Gamazon, and Jason B Nikas, and Lang Wu
Department of Pharmacy, Harbin Medical University Cancer Hospital, Harbin, China.

A large proportion of heritability for prostate cancer risk remains unknown. Transcriptome-wide association study combined with validation comparing overall levels will help to identify candidate genes potentially playing a role in prostate cancer development. Using data from the Genotype-Tissue Expression Project, we built genetic models to predict normal prostate tissue gene expression using the statistical framework PrediXcan, a modified version of the unified test for molecular signatures and Joint-Tissue Imputation. We applied these prediction models to the genetic data of 79 194 prostate cancer cases and 61 112 controls to investigate the associations of genetically determined gene expression with prostate cancer risk. Focusing on associated genes, we compared their expression in prostate tumor vs normal prostate tissue, compared methylation of CpG sites located at these loci in prostate tumor vs normal tissue, and assessed the correlations between the differentiated genes' expression and the methylation of corresponding CpG sites, by analyzing The Cancer Genome Atlas (TCGA) data. We identified 573 genes showing an association with prostate cancer risk at a false discovery rate (FDR) ≤ 0.05, including 451 novel genes and 122 previously reported genes. Of the 573 genes, 152 showed differential expression in prostate tumor vs normal tissue samples. At loci of 57 genes, 151 CpG sites showed differential methylation in prostate tumor vs normal tissue samples. Of these, 20 CpG sites were correlated with expression of 11 corresponding genes. In this TWAS, we identified novel candidate susceptibility genes for prostate cancer risk, providing new insights into prostate cancer genetics and biology.

UI MeSH Term Description Entries
D008297 Male Males
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D011471 Prostatic Neoplasms Tumors or cancer of the PROSTATE. Cancer of Prostate,Prostate Cancer,Cancer of the Prostate,Neoplasms, Prostate,Neoplasms, Prostatic,Prostate Neoplasms,Prostatic Cancer,Cancer, Prostate,Cancer, Prostatic,Cancers, Prostate,Cancers, Prostatic,Neoplasm, Prostate,Neoplasm, Prostatic,Prostate Cancers,Prostate Neoplasm,Prostatic Cancers,Prostatic Neoplasm
D005500 Follow-Up Studies Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease. Followup Studies,Follow Up Studies,Follow-Up Study,Followup Study,Studies, Follow-Up,Studies, Followup,Study, Follow-Up,Study, Followup
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D014408 Biomarkers, Tumor Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or BODY FLUIDS. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including HORMONES; ANTIGENS; amino and NUCLEIC ACIDS; ENZYMES; POLYAMINES; and specific CELL MEMBRANE PROTEINS and LIPIDS. Biochemical Tumor Marker,Cancer Biomarker,Carcinogen Markers,Markers, Tumor,Metabolite Markers, Neoplasm,Tumor Biomarker,Tumor Marker,Tumor Markers, Biochemical,Tumor Markers, Biological,Biochemical Tumor Markers,Biological Tumor Marker,Biological Tumor Markers,Biomarkers, Cancer,Marker, Biochemical Tumor,Marker, Biologic Tumor,Marker, Biological Tumor,Marker, Neoplasm Metabolite,Marker, Tumor Metabolite,Markers, Biochemical Tumor,Markers, Biological Tumor,Markers, Neoplasm Metabolite,Markers, Tumor Metabolite,Metabolite Markers, Tumor,Neoplasm Metabolite Markers,Tumor Markers, Biologic,Tumor Metabolite Marker,Biologic Tumor Marker,Biologic Tumor Markers,Biomarker, Cancer,Biomarker, Tumor,Cancer Biomarkers,Marker, Tumor,Markers, Biologic Tumor,Markers, Carcinogen,Metabolite Marker, Neoplasm,Metabolite Marker, Tumor,Neoplasm Metabolite Marker,Tumor Biomarkers,Tumor Marker, Biochemical,Tumor Marker, Biologic,Tumor Marker, Biological,Tumor Markers,Tumor Metabolite Markers
D014481 United States A country in NORTH AMERICA between CANADA and MEXICO.
D015972 Gene Expression Regulation, Neoplastic Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control of gene action in neoplastic tissue. Neoplastic Gene Expression Regulation,Regulation of Gene Expression, Neoplastic,Regulation, Gene Expression, Neoplastic
D016022 Case-Control Studies Comparisons that start with the identification of persons with the disease or outcome of interest and a control (comparison, referent) group without the disease or outcome of interest. The relationship of an attribute is examined by comparing both groups with regard to the frequency or levels of outcome over time. Case-Base Studies,Case-Comparison Studies,Case-Referent Studies,Matched Case-Control Studies,Nested Case-Control Studies,Case Control Studies,Case-Compeer Studies,Case-Referrent Studies,Case Base Studies,Case Comparison Studies,Case Control Study,Case Referent Studies,Case Referrent Studies,Case-Comparison Study,Case-Control Studies, Matched,Case-Control Studies, Nested,Case-Control Study,Case-Control Study, Matched,Case-Control Study, Nested,Case-Referent Study,Case-Referrent Study,Matched Case Control Studies,Matched Case-Control Study,Nested Case Control Studies,Nested Case-Control Study,Studies, Case Control,Studies, Case-Base,Studies, Case-Comparison,Studies, Case-Compeer,Studies, Case-Control,Studies, Case-Referent,Studies, Case-Referrent,Studies, Matched Case-Control,Studies, Nested Case-Control,Study, Case Control,Study, Case-Comparison,Study, Case-Control,Study, Case-Referent,Study, Case-Referrent,Study, Matched Case-Control,Study, Nested Case-Control
D044127 Epigenesis, Genetic A genetic process by which the adult organism is realized via mechanisms that lead to the restriction in the possible fates of cells, eventually leading to their differentiated state. Mechanisms involved cause heritable changes to cells without changes to DNA sequence such as DNA METHYLATION; HISTONE modification; DNA REPLICATION TIMING; NUCLEOSOME positioning; and heterochromatization which result in selective gene expression or repression. Epigenetic Processes,Epigenetic Process,Epigenetics Processes,Genetic Epigenesis,Process, Epigenetic,Processes, Epigenetic,Processes, Epigenetics

Related Publications

Duo Liu, and Jingjing Zhu, and Dan Zhou, and Emily G Nikas, and Nikos T Mitanis, and Yanfa Sun, and Chong Wu, and Nicholas Mancuso, and Nancy J Cox, and Liang Wang, and Stephen J Freedland, and Christopher A Haiman, and Eric R Gamazon, and Jason B Nikas, and Lang Wu
October 2020, Journal of the National Cancer Institute,
Duo Liu, and Jingjing Zhu, and Dan Zhou, and Emily G Nikas, and Nikos T Mitanis, and Yanfa Sun, and Chong Wu, and Nicholas Mancuso, and Nancy J Cox, and Liang Wang, and Stephen J Freedland, and Christopher A Haiman, and Eric R Gamazon, and Jason B Nikas, and Lang Wu
July 2023, HGG advances,
Duo Liu, and Jingjing Zhu, and Dan Zhou, and Emily G Nikas, and Nikos T Mitanis, and Yanfa Sun, and Chong Wu, and Nicholas Mancuso, and Nancy J Cox, and Liang Wang, and Stephen J Freedland, and Christopher A Haiman, and Eric R Gamazon, and Jason B Nikas, and Lang Wu
April 2019, Cancer research,
Duo Liu, and Jingjing Zhu, and Dan Zhou, and Emily G Nikas, and Nikos T Mitanis, and Yanfa Sun, and Chong Wu, and Nicholas Mancuso, and Nancy J Cox, and Liang Wang, and Stephen J Freedland, and Christopher A Haiman, and Eric R Gamazon, and Jason B Nikas, and Lang Wu
May 2023, medRxiv : the preprint server for health sciences,
Duo Liu, and Jingjing Zhu, and Dan Zhou, and Emily G Nikas, and Nikos T Mitanis, and Yanfa Sun, and Chong Wu, and Nicholas Mancuso, and Nancy J Cox, and Liang Wang, and Stephen J Freedland, and Christopher A Haiman, and Eric R Gamazon, and Jason B Nikas, and Lang Wu
December 2021, Human molecular genetics,
Duo Liu, and Jingjing Zhu, and Dan Zhou, and Emily G Nikas, and Nikos T Mitanis, and Yanfa Sun, and Chong Wu, and Nicholas Mancuso, and Nancy J Cox, and Liang Wang, and Stephen J Freedland, and Christopher A Haiman, and Eric R Gamazon, and Jason B Nikas, and Lang Wu
August 2023, Omics : a journal of integrative biology,
Duo Liu, and Jingjing Zhu, and Dan Zhou, and Emily G Nikas, and Nikos T Mitanis, and Yanfa Sun, and Chong Wu, and Nicholas Mancuso, and Nancy J Cox, and Liang Wang, and Stephen J Freedland, and Christopher A Haiman, and Eric R Gamazon, and Jason B Nikas, and Lang Wu
August 2019, Human genomics,
Duo Liu, and Jingjing Zhu, and Dan Zhou, and Emily G Nikas, and Nikos T Mitanis, and Yanfa Sun, and Chong Wu, and Nicholas Mancuso, and Nancy J Cox, and Liang Wang, and Stephen J Freedland, and Christopher A Haiman, and Eric R Gamazon, and Jason B Nikas, and Lang Wu
June 2024, HGG advances,
Duo Liu, and Jingjing Zhu, and Dan Zhou, and Emily G Nikas, and Nikos T Mitanis, and Yanfa Sun, and Chong Wu, and Nicholas Mancuso, and Nancy J Cox, and Liang Wang, and Stephen J Freedland, and Christopher A Haiman, and Eric R Gamazon, and Jason B Nikas, and Lang Wu
July 2018, Nature genetics,
Duo Liu, and Jingjing Zhu, and Dan Zhou, and Emily G Nikas, and Nikos T Mitanis, and Yanfa Sun, and Chong Wu, and Nicholas Mancuso, and Nancy J Cox, and Liang Wang, and Stephen J Freedland, and Christopher A Haiman, and Eric R Gamazon, and Jason B Nikas, and Lang Wu
June 2023, American journal of human genetics,
Copied contents to your clipboard!